Halozyme Therapeutics (HALO) is on the list of such stocks currently recommended by our proprietary system. In addition to a favorable Growth Score, it carries a top Zacks Rank.

H.C. Wainwright raised the firm’s price target on Halozyme (HALO) to $70 from $68 and keeps a Buy rating on the shares. The company has strong ...

Piper Sandler raised the firm’s price target on Halozyme (HALO) to $53 from $52 and keeps a Neutral rating on the shares after maintaining FY24 ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Shares of Sana Biotechnology SANA skyrocketed 151.5% in the past week after the company announced positive initial results ...

Alnylam Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating ...

The Bank of Israel set the representative shekel-dollar rate down 0.248% from Monday, at NIS 3.627/$. Information ...

Calling people "mentally ill" based on their sexual identity and referring to women as "household objects" will now be allowed in the context of political discussions on social media giant Meta's ...